USANA Health Sciences, Inc. (USNA) Major Shareholder Sells $481,146.89 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) major shareholder Global Ltd Gull sold 7,289 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $66.01, for a total transaction of $481,146.89. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Global Ltd Gull also recently made the following trade(s):

  • On Thursday, November 2nd, Global Ltd Gull sold 43,292 shares of USANA Health Sciences stock. The shares were sold at an average price of $65.25, for a total transaction of $2,824,803.00.
  • On Thursday, October 26th, Global Ltd Gull sold 60,871 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.39, for a total transaction of $4,102,096.69.
  • On Monday, October 30th, Global Ltd Gull sold 93,443 shares of USANA Health Sciences stock. The shares were sold at an average price of $67.08, for a total transaction of $6,268,156.44.
  • On Thursday, September 14th, Global Ltd Gull sold 79,294 shares of USANA Health Sciences stock. The shares were sold at an average price of $57.61, for a total transaction of $4,568,127.34.
  • On Tuesday, September 5th, Global Ltd Gull sold 40,000 shares of USANA Health Sciences stock. The shares were sold at an average price of $58.41, for a total transaction of $2,336,400.00.

USANA Health Sciences, Inc. (NYSE:USNA) opened at $65.85 on Thursday. The company has a market cap of $1,582.31, a price-to-earnings ratio of 17.45 and a beta of 1.07. USANA Health Sciences, Inc. has a one year low of $52.55 and a one year high of $71.00.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.38%. The company had revenue of $261.77 million during the quarter, compared to analysts’ expectations of $259.52 million. During the same quarter in the prior year, the company posted $2.40 EPS. The business’s revenue was up 3.0% on a year-over-year basis. equities research analysts expect that USANA Health Sciences, Inc. will post 3.7 EPS for the current year.

USANA Health Sciences declared that its Board of Directors has initiated a share repurchase plan on Tuesday, July 25th that allows the company to repurchase $64.60 million in shares. This repurchase authorization allows the company to reacquire up to 46% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

WARNING: This piece was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://www.themarketsdaily.com/2017/11/16/usana-health-sciences-inc-usna-major-shareholder-sells-481146-89-in-stock.html.

Several hedge funds have recently made changes to their positions in the company. Alps Advisors Inc. raised its stake in shares of USANA Health Sciences by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 8,349 shares of the company’s stock valued at $535,000 after buying an additional 22 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of USANA Health Sciences by 0.5% in the 2nd quarter. California State Teachers Retirement System now owns 20,582 shares of the company’s stock valued at $1,319,000 after buying an additional 100 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of USANA Health Sciences by 1.2% in the 1st quarter. JPMorgan Chase & Co. now owns 16,044 shares of the company’s stock valued at $924,000 after buying an additional 196 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of USANA Health Sciences by 13.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock valued at $135,000 after buying an additional 245 shares in the last quarter. Finally, Legal & General Group Plc raised its stake in shares of USANA Health Sciences by 7.6% in the 2nd quarter. Legal & General Group Plc now owns 4,040 shares of the company’s stock valued at $259,000 after buying an additional 284 shares in the last quarter. Institutional investors own 44.54% of the company’s stock.

Several research firms recently commented on USNA. BidaskClub upgraded shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Pivotal Research cut their target price on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, July 26th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply